Debbie Rigby rounds up the latest in research news
Acetylcholinesterase inhibitors (AChEIs) and memantine are commonly used in the management of dementia. A systematic review and meta-analysis of 80 trials has demonstrated a modest effect at 6 months for AChEIs versus control on MMSE scores which is moderated by dementia subtype. The effect of treatment versus control twice as high for patients with Parkinson disease dementia/ dementia with Lewy bodies (2.11 MMSE points at 6 months) as for patients with Alzheimer disease/vascular dementia (0.91 MMSE points at 6 months). For memantine the effect is smaller.
Dement Geriatr Cogn Disord 2018;45:131–151.
Non-vitamin K antagonist oral anticoagulants (NOACs) are an alternative for vitamin K antagonists (VKAs) to prevent stroke in patients with atrial fibrillation (AF), and have emerged as the preferred choice, particularly in patients newly started on anticoagulation. This article provides a summary guide for optimal use of NOACs.
Turmeric has consistently been demonstrated to produce analgesic and anti‐inflammatory effects in animal models and in clinical trials, and appears to have less serious adverse effects than many current analgesics. Turmeric (curcumin) appears to be a possible candidate for consideration for use as a stand‐alone analgesic, or in analgesic combinations as part of opioid‐, NSAID‐ or paracetamol sparing strategies.
Journal of Clinical Pharmacy and Therapeutics 2018
Bleeding is commonly cited as a reason for stopping oral anticoagulants. Nuisance bleeding is common among AF patients on oral anticoagulants. However, in this study nuisance bleeding was not associated with a higher risk of major bleeding or SSE over the next 6 months, suggesting its occurrence should not lead to changes in anticoagulation treatment strategies in OAC-treated patients.